Commentary: This university is rolling out the COVID-19 vaccine for staff and students. It's a lot of work
Much goes into a vaccine rollout: Critical data tracking, complicated storage and the intricacies of actually administering doses, says an expert.
SAN FRANCISCO: In late October, I received an email from a member of the California Department of Public Health.
I called the number in the email and a bright happy voice answered and asked if the University of California, San Francisco (UCSF) would be interested in the early release and distribution of the Pfizer COVID-19 vaccine.
Of course, I said yes.
I am the chief pharmacy executive at UCSF Health and associate dean and clinical professor at the School of Pharmacy.
My team and I are responsible for the distribution of all medications and vaccines throughout the health system, and I am also the person running much of the COVID-19 vaccine distribution for UCSF.
UCSF will be receiving our first allocation of the Pfizer vaccine around Dec 15 and the Moderna vaccine sometime soon after that.
READ: Commentary: A vaccine is on the horizon. But most Singaporeans are adopting a wait-and-see attitude
READ: Commentary: Concerns over severe allergic reactions to COVID-19 vaccines don't outweigh benefits of vaccination
We project that by the end of 2020, we will receive enough vaccines for all our staff, students, faculty and most of our high-risk patient populations.
This news is incredibly exciting, but will take a lot of work to pull off smoothly.
My colleagues and I are working to make sure that critical data tracking, complicated storage and the intricacies of actually administering doses all run smoothly so that these vaccines are distributed as equitably and efficiently as possible.
READ: Pfizer-BioNTech COVID-19 vaccine approved by Singapore, first shipment expected by end-December
TRACKING, STORAGE AND PREPARATION
Before the US Centers for Disease Control and Prevention (CDC) would give us any vaccines, the first thing I needed to do was register the UCSF health system with the California Department of Public Health.
I give them information on everything from the number of our medical workers who are qualified to administer the vaccine to the serial numbers of our freezers.
As a precaution, since many are considering this vaccine “liquid gold,” our team needs to account for every dose at every step of the process due to the potential of diversion.
We also aren’t yet sure how many vaccines UCSF will be allocated in these first rounds, so we need to be prepared to store either a small or large supply.
The pharmacies storing the vaccine are highly regulated, monitored and secured spaces. The vaccines will not only be on a secure and backup power supply in case of electrical power outage but also electronically monitored for temperature.
READ: Commentary: The challenge of keeping COVID-19 vaccines at sub-zero temperatures during distribution
READ: Commentary: So the vaccines are here, but how will they get to billions across the globe?
Unlike the flu vaccine, both the Pfizer and Moderna COVID-19 vaccines have unique storage requirements, last at room temperature for only a short amount of time and require a lot of preparation.
First, you can’t store either the Pfizer or Moderna vaccine on a refrigerator shelf. The Pfizer vaccine comes in a frozen liquid form that needs ultra-cold storage at -70 degrees Celsius.
In this deep freeze, it is stable for six months, but it takes specific preparation before it is ready to give to people.
Pharmacists and technicians have to thaw the frozen liquid and then mix it into a solution of sterile, preservative-free saline.
Each Pfizer vaccine vial contains five doses and is stable for only six hours at room temperature. The Moderna vaccine is supplied in liquid form with 10 doses per vial.
When it is time to give people the vaccine, each dose has to be prepared and labeled in a ready-to-use syringe.
At each step of this process, our staff will document and track every dose. Once we begin vaccinating people, we will send the California Department of Public Health and the CDC an accountability log of how many doses we administer each day.
READ: Moderna confirms agreement with MOH to supply Singapore with COVID-19 vaccine
WHO GETS VACCINATED FIRST?
Once UCSF receives our first vaccine shipment, we face the task of deciding who gets these precious vaccines first.
Our team has utilised national guidelines from the CDC and the Advisory Committee on Immunization Practices as well as state guidance from the California Department of Public Health to follow the phased prioritisation rollout.
Right now, we are focusing on phase 1a, which broadly includes healthcare workers and first responders as well as high-risk patients and long-term care facility residents.
READ: Commentary: Great news, the first approved COVID-19 vaccine is here. But don't throw away your masks yet
While the guidance says which groups should be prioritised, there is no way it could cover every decision. Our team has been working with doctors, ethicists and experts in health equity to further prioritise the most vulnerable first responders, high-risk staff and high-risk patients within the University of California system.
We are looking at not only clinical healthcare workers, clinical students and patients, but anyone who could have prolonged, repeated potential exposure to body fluids and aerosols.
That includes critical staff like medical transporters who get patients where they need to be, food service workers, police officers and environmental services workers in our hospitals and clinics.
READ: Commentary: Young or old first? Timing of COVID-19 vaccination could decide
On Dec 3, California Governor Gavin Newsom announced that the state will receive 327,000 doses of the Pfizer vaccine by the middle of December and 2.2 million doses by the New Year.
Giving this vaccine to millions of Californians is going to be a massive undertaking. But our team and health systems throughout the US have been preparing so that this rollout is as effective, efficient and fair as possible.
Listen to infectious disease experts discuss what a COVID-19 vaccine rollout would look like:
BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments
Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram
Desi Kotis is Associate Dean and Professor of Pharmacy at the University of California, San Francisco. This commentary first appeared on The Conversation.